2007 - Thiazolidinediones increased risk for heart failure, myocardial infarction, and death in older patients with type 2 diabetes

Padwal, Raj
June 2008
ACP Journal Club;6/20/2008, Vol. 148 Issue 4, p12
Academic Journal
The article discusses whether thiazolidinediones (TZDs) increase risk for heart failure (HF), myocardial infarction (MI), and mortality more than other oral hypoglycemic agents in older patients with type 2 diabetes. Nested case-control study in a retrospective cohort study with a median follow-up of 3.8 years was conducted. It is concluded that TZDs, particularly rosiglitazone, were associated with higher risks for HF, MI, and mortality than other oral hypoglycemic agents.


Related Articles

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk.  // Clinical Oncology Alert;Jul2007, Vol. 23 Issue 7, p1 

    The article reports on the association of heart failure with rosiglitazone use. It states that the U.S. Food and Drug Administration (FDA) will give a black box warning to the drug which is used for treating type 2 diabetes. Based on a study conducted, there was no evidence of an increased death...

  • NICE raises concern over rosiglitazone.  // Pulse;10/15/2008, Vol. 68 Issue 35, p10 

    The article reports on the concern raised by the National Institute for Health and Clinical Excellence (NICE) over the safety of rosiglitazone for the management of type 2 diabetes. The draft NICE guidance highlights evidence suggesting rosiglitazone increases the risk of heart attacks, although...

  • Are Thiazolidinediones (TZDs) Safe?  // Clinical Cardiology Alert;Nov2007, Vol. 26 Issue 11, p1 

    The article focuses on the safety of thiazolidinediones (TZDs), rosiglitazone and pioglitazone. A paper published in the "Journal of American Medical Association" associated pioglitazone with lower risk of death, myocardial infarction or stroke among patients with diabetes. Another paper linked...

  • Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. Boussageon, Rémy; Supper, Irène; Bejan-Angoulvant, Theodora; Kellou, Nadir; Cucherat, Michel; Boissel, Jean-Pierre; Kassai, Behrouz; Moreau, Alain; Gueyffier, François; Cornu, Catherine // PLoS Medicine;Apr2012, Vol. 9 Issue 4, p1 

    Background: The UK Prospective Diabetes Study showed that metformin decreases mortality compared to diet alone patients with type 2 diabetes mellitus. Since then, it has been the first-line treatment in overweight patients with type 2 diabetes. However, metformin-sulphonylurea bitherapy may...

  • Mixed results for Rosiglitazone.  // Cardiovascular Devices & Drugs;Jul2009, Vol. 15 Issue 7, p13 

    The article deals with a study published in "The Lancet," which examined the use of rosiglitazone in combination with standard diabetes treatments in lowering blood glucose in Type 2 diabetics. Cardiovascular hospitalisation or death was the primary endpoint of the study. Results of the study...

  • Reduced Mortality Associated with Metformin Use in Type 2 Diabetes: A Population-Based Cohort Study. Gregoire, Jean-Pierre; Sirois, Caroline; Jobin, Marie-Sophie; Demers, Eric; Kessabi, Sophia; Barbeau, Martin; Moisan, Jocelyne // Diabetes;Jun2007 Supplement 1, Vol. 56, pA239 

    Recently published results from observational studies suggest that compared with sulfunylurea therapy (SU), metformin (MET) may protect against mortality whereas the effect of MET and SU combination has on mortality is controversial. These studies were however conducted on data gathered in the...

  • In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events. Bhatt, D. L. // Annals of Internal Medicine;1/21/2014, Vol. 160 Issue 2, Special Section pJC9 

    The article discusses a study which compares efficacy and safety of saxagliptin with placebo for cardiovascular (CV) outcomes in at-risk patients with type 2 diabetes mellitus. The study compared outcomes from saxagliptin and placebo in case of nonfatal myocardial infarction, hospitalization for...

  • Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. Yuiuf, Salim // ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p43 

    The article focuses on a study by researcher K. Malmberg and colleagues, which found that intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. The study found that in patients with type 2...

  • Rosiglitazone or pioglitazone in type 2 diabetes? De Vries, Corinne S.; Russell-Jones, David L. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p324 

    The article discusses research on the safety of thiazolidinediones, rosiglitazone and pioglitazone, in type 2 diabetes. It references the study "Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study," by D. N. Juurlink and colleagues,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics